Back to Search
NIKHIL MUNSHI, MD, PHD
MD, PHD
Internal Medicine Physician
NPI: 1457370249IndividualAccepts Medicare
Specialties, Licenses & Credentials
Internal Medicine PhysicianPrimary
Internal Medicine
Code: 207R00000X
M3658(TX)
Education
COLUMBIA UNIVERSITY COLLEGE OF PHYSICIANS AND SURGEONS
Class of 2003
Research & Publications (20)
Cx30.2 enhancer analysis identifies Gata4 as a novel regulator of atrioventricular delay.
PMID 19592579·Development·2009
7-preclinical
Antimyeloma activity of the orally bioavailable dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
PMID 19584292·Cancer Res·2009
7-preclinical
International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).
PMID 19554029·Leukemia·2009
6-review
The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo.
PMID 19509164·Clin Cancer Res·2009
7-preclinical
Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy.
PMID 19528374·J Clin Oncol·2009
8-other
Identification of novel antigens with induced immune response in monoclonal gammopathy of undetermined significance.
PMID 19587378·Blood·2009
8-other
Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens.
PMID 19561323·Blood·2009
8-other
Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma.
PMID 19417213·Blood·2009
7-preclinical
Primary hyperoxaluria causing ESRD and gangrene of extremities leading to amputation.
PMID 19549164·Hemodial Int·2009
5-case
Biologic sequelae of I{kappa}B kinase (IKK) inhibition in multiple myeloma: therapeutic implications.
PMID 19270264·Blood·2009
8-other
Sinus tracts--an early sign of bisphosphonate-associated osteonecrosis of the jaws?
PMID 19231786·J Oral Maxillofac Surg·2009
8-other
Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma.
PMID 19151776·Leukemia·2009
7-preclinical
CXCR4 inhibitor AMD3100 disrupts the interaction of multiple myeloma cells with the bone marrow microenvironment and enhances their sensitivity to therapy.
PMID 19139079·Blood·2009
7-preclinical
Lenalidomide and rituximab in Waldenstrom's macroglobulinemia.
PMID 19118065·Clin Cancer Res·2009
3-trial
Bortezomib induces canonical nuclear factor-kappaB activation in multiple myeloma cells.
PMID 19436050·Blood·2009
7-preclinical
Dysfunctional homologous recombination mediates genomic instability and progression in myeloma.
PMID 19050310·Blood·2009
8-other
Targeting PKC: a novel role for beta-catenin in ER stress and apoptotic signaling.
PMID 19018094·Blood·2009
8-other
Emerging treatments for multiple myeloma: beyond immunomodulatory drugs and bortezomib.
PMID 19389500·Semin Hematol·2009
6-review
Plasma cell disorders: an historical perspective.
PMID 19074099·Hematology Am Soc Hematol Educ Program·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 5323 HARRY HINES BLVD
DALLAS, TX 75390 - Phone
- (214) 648-4001
Quick Facts
- NPI
- 1457370249
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 23
- Publications
- 20
Are you this provider?
Claim Your Profile